{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renal+Cell+Carcinoma%2C+Clear+Cell&page=31", "query": { "condition": "Renal Cell Carcinoma, Clear Cell", "page": 31 }, "page_size": 10 }, "pagination": { "page": 31, "page_size": 10, "total_count": 999, "total_pages": 100, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renal+Cell+Carcinoma%2C+Clear+Cell&page=32&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renal+Cell+Carcinoma%2C+Clear+Cell&page=30&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T12:54:04.043Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00378703", "title": "Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Recurrent Renal Cell Carcinoma", "Stage IV Renal Cell Cancer AJCC v7" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Sorafenib Tosylate", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 361, "start_date": "2007-09-14", "completion_date": "2017-03-21", "has_results": true, "last_update_posted_date": "2018-11-14", "last_synced_at": "2026-10-15T12:54:04.043Z", "location_count": 558, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 356 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00378703" }, { "nct_id": "NCT00459979", "title": "Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "sunitinib malate", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2007-03", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2014-03-07", "last_synced_at": "2026-10-15T12:54:04.043Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00459979" }, { "nct_id": "NCT00335556", "title": "Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Childhood Renal Cell Carcinoma", "Clear Cell Renal Cell Carcinoma", "Clear Cell Sarcoma of the Kidney", "Papillary Renal Cell Carcinoma", "Rhabdoid Tumor of the Kidney", "Stage I Renal Cell Cancer", "Stage I Renal Wilms Tumor", "Stage II Renal Cell Cancer", "Stage II Renal Wilms Tumor", "Stage III Renal Cell Cancer", "Stage III Renal Wilms Tumor", "Stage IV Renal Cell Cancer", "Stage IV Renal Wilms Tumor" ], "interventions": [ { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Conventional Surgery", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Dactinomycin", "type": "BIOLOGICAL" }, { "name": "Vincristine Sulfate", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL", "RADIATION", "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "29 Years", "sex": "ALL", "summary": "Up to 29 Years" }, "enrollment_count": 291, "start_date": "2006-06", "completion_date": null, "has_results": true, "last_update_posted_date": "2017-07-21", "last_synced_at": "2026-10-15T12:54:04.043Z", "location_count": 161, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 127 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00335556" }, { "nct_id": "NCT03024996", "title": "A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 778, "start_date": "2017-01-03", "completion_date": "2022-12-08", "has_results": true, "last_update_posted_date": "2023-08-03", "last_synced_at": "2026-10-15T12:54:04.043Z", "location_count": 45, "location_summary": "Scottsdale, Arizona • Duarte, California • Lancaster, California + 37 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03024996" }, { "nct_id": "NCT01689766", "title": "Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Renal Cell Carcinoma" ], "interventions": [ { "name": "Technetium Tc 99m EC20", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Endocyte", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2003-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2023-07-25", "last_synced_at": "2026-10-15T12:54:04.043Z", "location_count": 2, "location_summary": "Rochester, Minnesota • Houston, Texas", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01689766" }, { "nct_id": "NCT00110344", "title": "Research Study for Patients With Metastatic Renal Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "Nexavar (Sorafenib, BAY43-9006)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2005-11", "completion_date": "2006-06", "has_results": false, "last_update_posted_date": "2013-10-11", "last_synced_at": "2026-10-15T12:54:04.043Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00110344" }, { "nct_id": "NCT05579847", "title": "Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination Immunotherapy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Renal Cell Carcinoma Stage IV" ], "interventions": [ { "name": "mHealth Smart Phone Application", "type": "OTHER" }, { "name": "eHEALS digital literacy test", "type": "BEHAVIORAL" }, { "name": "Weekly Quiz", "type": "BEHAVIORAL" }, { "name": "European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire", "type": "BEHAVIORAL" }, { "name": "Patient Post Intervention Survey", "type": "BEHAVIORAL" } ], "intervention_types": [ "OTHER", "BEHAVIORAL" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2022-10-19", "completion_date": "2024-11-04", "has_results": false, "last_update_posted_date": "2025-12-04", "last_synced_at": "2026-10-15T12:54:04.043Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05579847" }, { "nct_id": "NCT01712685", "title": "Imaging Studies of Kidney Cancer Using 18F-VM4-037", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Renal Cell", "Kidney Neoplasms" ], "interventions": [ { "name": "18F-VM4-037", "type": "DRUG" }, { "name": "PET/CT", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2012-10", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2017-01-11", "last_synced_at": "2026-10-15T12:54:04.043Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01712685" }, { "nct_id": "NCT04440943", "title": "A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Breast Cancer", "Gastric Cancer", "Renal Cell Carcinoma", "Ovarian Cancer", "Primary Peritoneal Carcinoma", "Fallopian Tube Cancer", "Cholangiocarcinoma", "Bladder Urothelial Carcinoma", "MSI-H Colorectal Cancer", "Esophageal Cancer", "Hepatic Cancer", "Head and Neck Cancer", "Other Solid Tumors" ], "interventions": [ { "name": "CDX-527", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2020-08-04", "completion_date": "2023-04-06", "has_results": false, "last_update_posted_date": "2023-06-18", "last_synced_at": "2026-10-15T12:54:04.043Z", "location_count": 5, "location_summary": "Atlanta, Georgia • Chicago, Illinois • Omaha, Nebraska + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04440943" }, { "nct_id": "NCT00002847", "title": "Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Blumenthal Cancer Center at Carolinas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "1995-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-19", "last_synced_at": "2026-10-15T12:54:04.043Z", "location_count": 1, "location_summary": "Charlotte, North Carolina", "locations": [ { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002847" } ] }